雷蛇(01337.HK):控股及主要股东折让逾7%配售2.75亿股 涉套6.6亿元
雷蛇(01337.HK)公布,接获公司主席兼首席执行官陈民亮,及公司非执行董事LIM Kaling通知,於今日(6月3日),陈民亮连同Lim Teck Lee Land及Archview Capital与配售代理,以每股股份2.405元出售合共2.75亿股公司股份,待售股份占公司已发行股本之3.09%。
每股配售价较昨日收市价折让7.5%,涉套现6.61亿元。
於配售完成後,陈民亮及LIM Kaling之持股比例分别降至33.76%及23.06%,仍分别是公司控股股东及主要股东。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.